ArticleFrontiers in oncology2025

First-line immune checkpoint inhibitors in older adults (≥75 years) with advanced esophageal squamous cell carcinoma: efficacy and safety.

Lin-Lin Zheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.